Signal Intelligence
The shape of the signal. An SI-written weekly briefing, plus volume, momentum, what is rising and falling, and where power is concentrating — derived live from every story and study the Wire has ingested. No vanity metrics, just the raw flow.
Visualizing the Phase Transition
Drug discovery timelines are compressing exponentially. The Frontiers tab reflects live data from our Cure Tracker.
11.5 yrs
Avg approval time (2000)
Traditional path
2.3 yrs
Avg approval time (2025)
SI-accelerated
5-50×
Pipeline compression
By stage
50+
Accelerated approvals
In 2025 alone
The Approval Acceleration Curve
FDA DRUG APPROVAL TIMELINE VS ACCELERATED PATHWAY USAGE · 1990-2025
The lines are crossing: average approval time has dropped 80% since 2000 while accelerated pathway usage has grown 50×. This is not incremental improvement. It is a phase transition.
Directional industry estimates synthesized from FDA, Nature Reviews Drug Discovery, and PhRMA annual reports. Not live data.
Pipeline Stage Compression
TRADITIONAL VS SI-COMPRESSED DRUG DEVELOPMENT · MONTHS
Discovery is compressed 50× (years → weeks). The bottleneck has shifted to clinical trials: still compressed 6×, but regulatory endpoints remain the pacing constraint.
Compression factors are directional estimates based on industry case studies: individual programs vary widely.
Breakthrough Therapies: Investment vs Time-to-Approval
BUBBLE SIZE = PATIENT IMPACT SCORE
Harvoni (HCV cure) reached approval in just 3 years with $2.1B investment: the fastest paradigm shift in history. Gene therapies (Casgevy, Zolgensma) required more capital but are one-time cures.
Investment and timelines are approximate, compiled from SEC filings and published analyses.
The 2026 Token Launch Queue
The biggest crypto projects reportedly planning a token generation event in 2026, ranked by capital. We read each one through the only question the Cure Protocol cares about: is this capital widening to the many, or concentrating in the few?